2010
DOI: 10.1016/j.parkreldis.2010.06.004
|View full text |Cite
|
Sign up to set email alerts
|

Levodopa response in dementia with lewy bodies: A 1-year follow-up study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
39
1

Year Published

2013
2013
2022
2022

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 48 publications
(41 citation statements)
references
References 20 publications
1
39
1
Order By: Relevance
“…However, the risk of psychosis exacerbation is lower. Although the effectiveness of L-dopa for DLB is lower than PD, it may be beneficial to the motor symptoms in the long run [42,45]. 2 patients who are treated with selegiline have been reported an improvement in extrapyramidal symptoms, which suggest that monoamine oxidase B (MAOB) may have applied value in DLB therapy.…”
Section: Discussionmentioning
confidence: 99%
“…However, the risk of psychosis exacerbation is lower. Although the effectiveness of L-dopa for DLB is lower than PD, it may be beneficial to the motor symptoms in the long run [42,45]. 2 patients who are treated with selegiline have been reported an improvement in extrapyramidal symptoms, which suggest that monoamine oxidase B (MAOB) may have applied value in DLB therapy.…”
Section: Discussionmentioning
confidence: 99%
“…However some dementia with Lewy bodies patients might benefit of L-dopa in terms of motor and cognitive dysfunction and a trial with low-dose of L-dopa could be considered in these patients. 12,13 A comprehensive geriatric assessment should therefore be performed, in order to exclude moderate or severe dementia and to accurately identify possible risks and benefits of dopaminergic treatment.…”
Section: Short Communicationmentioning
confidence: 99%
“…Levodopa, the main drug of choice for the motor treatment in patients with PD, has been found to be not as effective in patients with DLB as in PD. [62][63][64][65] This drug has also been reported to cause psychosis as a significant side effect in patients with DLB. 63,64 If the motor syndrome is tolerable in patients with DLB, the treatment with Levodopa should be avoided.…”
Section: Motormentioning
confidence: 99%
“…[62][63][64][65] This drug has also been reported to cause psychosis as a significant side effect in patients with DLB. 63,64 If the motor syndrome is tolerable in patients with DLB, the treatment with Levodopa should be avoided. 66 Nevertheless, clinicians may use low dose of Levodopa if required.…”
Section: Motormentioning
confidence: 99%